Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03160794|
Recruitment Status : Recruiting
First Posted : May 19, 2017
Last Update Posted : December 6, 2019
In the clinical scenario of recurrent prostate cancer (PCa) post local therapy, current standard studies (bone scan and computed tomography) commonly fail to identify the recurrent disease location. In this study the investigator aims to prospectively map recurrent disease with the unique combination of whole-body MR anatomical imaging combined with a new high-sensitivity and PCa-specific PET probe (PSMA-targeted: [18F]DCFPyL) to provide precise localization information to target disseminated tumor deposits in men presenting with rising PSA after prostatectomy and radiotherapy (maximal local therapies). Moreover, we will consequently treat all identified disease with image-guided stereotactic ablative radiotherapy (SABR), which has shown tantalizing results achieving excellent tumor eradication rates with minimal toxicities. This study is uniquely positioned to enable the discovery of new biomarkers and the correlation of prognostic tests (e.g. genomic signatures) from the initial prostatectomy specimen with the PET-MR/CT imaging results and curative-intent treatment outcomes.
The significance of the proposed work towards a measurable impact in PCa care is important to emphasize. The study team believes this novel curative-intent approach will transform lives, as opposed to therapies that transiently impact incurable disease stages. Herein, the focus is on patients at the earliest point of the disease spectrum of recurrent PCa after curative-intent treatments. Our hypothesis is that PSMA-targeted [18F]DCFPyL PET-MR/CT allows earlier detection and localization of defined metastatic targets in these patients, at a stage amenable to image-guided curative-intent therapy.
|Condition or disease||Intervention/treatment||Phase|
|Post Prostatectomy||Diagnostic Test: [18F]DCFPyL PET/MRI scan Radiation: Stereotactic Ablative Radiotherapy||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||75 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)|
|Actual Study Start Date :||May 23, 2017|
|Estimated Primary Completion Date :||May 2021|
|Estimated Study Completion Date :||May 2021|
Experimental: [18F] DCFPyL PET/MRI
[18F] DCFPyL PET/MRI scans for patients with recurrent disease after radical prostatectomy and adjuvant/salvage radiotherapy.
Lesions identified through [18F] DCFPyL PET/MRI will be treated with stereotactic ablative radiotherapy (SABR) or surgery.
Diagnostic Test: [18F]DCFPyL PET/MRI scan
PET/MRI imaging using the radiotracer, [18F]DCFPyL
Radiation: Stereotactic Ablative Radiotherapy
SABR as treatment for lesions identified using [18F]DCFPyL PET/MRI
- To determine if [18F]DCFPyL PET-MR/CT can identify early oligometastatic disease in patients with a rising PSA and negative staging (CS and BS) after standard-of-care maximal local therapies. [ Time Frame: 3 years ]Endpoint: Detection rates and performance metrics of [18F]DCFPyL PET-MR/CT in the post-prostatectomy plus adjuvant/salvage RT setting.
- To determine if treating PET-MR/CT identified lesions with curative-intent treatment (e.g. stereotactic body radiation therapy or surgery) associated with favorable preliminary measures of clinical performance. [ Time Frame: 3 Years ]
- Proportion of patients achieving biochemical response: detectable PSA (<0.05ng/mL) in 2 consecutive measurements (at least 2 weeks apart) within 6 months of treatment); or > 50% PSA decline in 2 separate measurements at least 1 month apart within 6 months of treatment
- Metabolic [18F]DCFPyL response rate after treatment
- Treatment-related toxicities incidence as defined by CTCAE v4.0
- Time to initiation of salvage ADT after treatment
- Correlation between PSA kinetics and PET imaging parameters [ Time Frame: 6 months post SABR ]To explore the correlation between PSA kinetics and PET imaging parameters (SUV, dynamic data, volumetric studies)
- Correlate between tissue biomarker and distant disease [ Time Frame: 3 years ]To explore the correlation between tissue biomarkers from prostatectomy specimen (e.g. genomic signatures) and [18F]DCFPyL PET/MR-detected distant disease
- [18F]DCFPyL PET/MR and PET/CT comparison [ Time Frame: 3 years ]To determine concordance and compare performance between [18F]DCFPyL PET/MR and PET/CT
- Concordance of PET-MR/CT finding and histological confirmation of metastatic foci. [ Time Frame: 3 years ]To determine the concordance of PET-MR/CT findings and histological confirmation of metastatic foci.
- Biomarker correlates [ Time Frame: 3 years ]To explore blood, urine and tissue biomarker correlates of imaging features and radiotherapy tumour resposnse.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03160794
|Contact: Alejandro Berlin, MD||416-946-4501 ext email@example.com|
|Princess Margaret Cancer Centre||Recruiting|
|Toronto, Ontario, Canada, M5G 2M9|
|Contact: Alejandro Berlin, MD 416-946-4501 ext 5813 firstname.lastname@example.org|
|Principal Investigator: Alejandro Berlin, MD|
|Principal Investigator:||Alejandro Berlin, MD||Princess Margaret Cancer Centre - University Health Network|